中华实验眼科杂志
中華實驗眼科雜誌
중화실험안과잡지
CHINESE JOURNAL OF EXPERIMENTAL OPHTHALMOLOGY
2012年
3期
258-261
,共4页
严宇清%林泉%孔旻%何剑峰%陈迎迎%谢小薰%罗彬%梁皓
嚴宇清%林泉%孔旻%何劍峰%陳迎迎%謝小薰%囉彬%樑皓
엄우청%림천%공민%하검봉%진영영%사소훈%라빈%량호
视网膜母细胞瘤%癌-睾丸抗原%免疫治疗
視網膜母細胞瘤%癌-睪汍抗原%免疫治療
시망막모세포류%암-고환항원%면역치료
Retinoblastoma%Cancer testis antigen%Immunotherapy
背景 视网膜母细胞瘤(RB)的免疫治疗因创伤小、针对性强而受到广泛关注,寻求相关免疫原性较强的肿瘤抗原是免疫治疗的基础.NY-ESO-I和NY-SAR-35是癌-睾丸抗原(CTA)中的两种基因,检测其在RB组织中的表达可为RB的免疫治疗研究提供依据. 目的 研究RB中NY-ESO-1 mRNA、NY-SAR-35 mRNA的表达情况,探讨将其用于RB特异性免疫治疗靶抗原的可能性. 方法 收集15例RB患儿组织为RB组、12例非肿瘤病变部位视网膜组织为非肿瘤病变组,及22例眼部因其他眼部病变进行手术治疗获取的正常相关眼组织标本为正常组.采用逆转录聚合酶链反应(RT-PCR)检测待测组织标本中NY-ESO-1mRNA、NY-SAR-35 mRNA的表达;并按随机数字表法抽取RT-PCR检测的阳性产物直接进行DNA测序,对检测结果与肿瘤病理分级、肿瘤大小、临床分期等临床指标进行分析.结果 15例RB组织中有6例标本表达NY-ESO-1基因,9例标本表达NY-SAR-35基因;在12例非肿瘤病变视网膜组织及22例眼部正常组织中均未见到NY-ESO-1基因和NY-SAR-35基因的表达.NY-ESO-1基因和NY-SAR-35基因的表达均与患者的性别(P=0.426、0.822)、年龄(P=0.180、0.464)、病理分型(P=0.744、0.582)、肿瘤大小(P=0.760、0.790)、临床分期(P=0.868、0.707)等临床相关指标无明显关联.结论 NY-ESO-1基因及NY-SAR-35基因均可特异性地高表达于RB组织中,其表达率明显高于其他全身肿瘤,有可能成为RB特异性免疫治疗的靶抗原.
揹景 視網膜母細胞瘤(RB)的免疫治療因創傷小、針對性彊而受到廣汎關註,尋求相關免疫原性較彊的腫瘤抗原是免疫治療的基礎.NY-ESO-I和NY-SAR-35是癌-睪汍抗原(CTA)中的兩種基因,檢測其在RB組織中的錶達可為RB的免疫治療研究提供依據. 目的 研究RB中NY-ESO-1 mRNA、NY-SAR-35 mRNA的錶達情況,探討將其用于RB特異性免疫治療靶抗原的可能性. 方法 收集15例RB患兒組織為RB組、12例非腫瘤病變部位視網膜組織為非腫瘤病變組,及22例眼部因其他眼部病變進行手術治療穫取的正常相關眼組織標本為正常組.採用逆轉錄聚閤酶鏈反應(RT-PCR)檢測待測組織標本中NY-ESO-1mRNA、NY-SAR-35 mRNA的錶達;併按隨機數字錶法抽取RT-PCR檢測的暘性產物直接進行DNA測序,對檢測結果與腫瘤病理分級、腫瘤大小、臨床分期等臨床指標進行分析.結果 15例RB組織中有6例標本錶達NY-ESO-1基因,9例標本錶達NY-SAR-35基因;在12例非腫瘤病變視網膜組織及22例眼部正常組織中均未見到NY-ESO-1基因和NY-SAR-35基因的錶達.NY-ESO-1基因和NY-SAR-35基因的錶達均與患者的性彆(P=0.426、0.822)、年齡(P=0.180、0.464)、病理分型(P=0.744、0.582)、腫瘤大小(P=0.760、0.790)、臨床分期(P=0.868、0.707)等臨床相關指標無明顯關聯.結論 NY-ESO-1基因及NY-SAR-35基因均可特異性地高錶達于RB組織中,其錶達率明顯高于其他全身腫瘤,有可能成為RB特異性免疫治療的靶抗原.
배경 시망막모세포류(RB)적면역치료인창상소、침대성강이수도엄범관주,심구상관면역원성교강적종류항원시면역치료적기출.NY-ESO-I화NY-SAR-35시암-고환항원(CTA)중적량충기인,검측기재RB조직중적표체가위RB적면역치료연구제공의거. 목적 연구RB중NY-ESO-1 mRNA、NY-SAR-35 mRNA적표체정황,탐토장기용우RB특이성면역치료파항원적가능성. 방법 수집15례RB환인조직위RB조、12례비종류병변부위시망막조직위비종류병변조,급22례안부인기타안부병변진행수술치료획취적정상상관안조직표본위정상조.채용역전록취합매련반응(RT-PCR)검측대측조직표본중NY-ESO-1mRNA、NY-SAR-35 mRNA적표체;병안수궤수자표법추취RT-PCR검측적양성산물직접진행DNA측서,대검측결과여종류병리분급、종류대소、림상분기등림상지표진행분석.결과 15례RB조직중유6례표본표체NY-ESO-1기인,9례표본표체NY-SAR-35기인;재12례비종류병변시망막조직급22례안부정상조직중균미견도NY-ESO-1기인화NY-SAR-35기인적표체.NY-ESO-1기인화NY-SAR-35기인적표체균여환자적성별(P=0.426、0.822)、년령(P=0.180、0.464)、병리분형(P=0.744、0.582)、종류대소(P=0.760、0.790)、림상분기(P=0.868、0.707)등림상상관지표무명현관련.결론 NY-ESO-1기인급NY-SAR-35기인균가특이성지고표체우RB조직중,기표체솔명현고우기타전신종류,유가능성위RB특이성면역치료적파항원.
Background The immunotherapy for retinoblastoma(RB) is gradually concerned recent year.To seek relative immune-associated antigen is a basis of immunotherapy.NY-ESO-1 and NY-SAR-35 are two kinds of genes of cancer testis antigen( CTA ).To understand their expressions in RB tissue can offer index for relative study.Objective This study was to investigate the expressions of two CTA NY-ESO-1 and NY-SAR-35 in RB and explore the possibility of them as potentially promising targets for antigen-specific immunotherapy of RB. Methods The samples were obtained from 15 RB eyes,12 non-tumor retinopathy eyes and 22 normal eyes with other benign eye diseases.Reverse transcription polymerase chain reaction(RT-PCR) was used to detect the expressions of NY-ESO-1 mRNA and NY-SAR-35 mRNA in the samples.Genes of positive PCR results were sequenced randomly.The relevance of the expression of the two cancer-testis antigen genes with the clinical characteristics such as tumor stage,tumor size and clinical stage were analyzed.This study was approved by Ethic Committee of Guangxi Medical University.Written informed consent was obtained from each patient before operation. Results NY-ESO-1 mRNA was positively expressed in 6 RB samples and NY-SAR-35 mRNA was expressed in 9 RB samples.In the non-tumor retinopathy samples and normal eye tissues,NY-ESO-1 mRNA and NY-SAR-35 mRNA were absent.No significant relevances were found between the expressions of the NY-ESO-1 mRNA and NY-SAR-35 mRNA with clinical characteristics such as age ( P =0.426,0.822 ),gender ( P =0.180,0.464 ),pathological classification ( P =0.744,0.582 ),tumor size ( P =0.760,0.790),and clinical stage ( P =0.868,0.707 ). Conclusions NY-ESO-1 and NY-SAR-35 have high expressing frequencies in RB tissue and their expressions in RB have specificity.These results offer a clue for the identification of targets antigen of RB.